Error message

Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of /home/patently/domains/xepc.eu/public_html/includes/bootstrap.inc).
Deprecated function: Using ${var} in strings is deprecated, use {$var} instead in include_once() (line 1442 of /home/patently/domains/xepc.eu/public_html/includes/bootstrap.inc).
Deprecated function: Optional parameter $type declared before required parameter $nid is implicitly treated as a required parameter in include_once() (line 1442 of /home/patently/domains/xepc.eu/public_html/includes/bootstrap.inc).

T 0409/91 (Fuel oils) of 18.3.1993

European Case Law Identifier:

ECLI:EP:BA:1993:T040991.19930318

Date of decision:

18 March 1993

Case number:

T 0409/91

Application number:

IPC class:

Language of proceedings:

EN

Distribution:

Download and more information:

Decision text in EN (PDF, 575Â KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in:	EN
Versions:	OJ \| Published

Title of application:

-

Applicant name:

Exxon

Opponent name:

-

Board:

3.3.01

Headnote:

The questions of sufficiency and of support by the description are questions of fact which have to be answered on the basis of the available evidence having regard to the balance of probabilities in each individual case. Although the requirements of sufficient disclosure of the invention (Art. 83 EPC) and support by the description (Art. 84 EPC) are related to different parts of the patent application, they give effect to the same legal principle that the patent monopoly should be justified by the technical contribution to the art. Therefore, the extent to which an invention is sufficiently disclosed is also highly relevant for the answer to the question of support (points 3.3 to 3.5 of the Reasons).

Relevant legal provisions:

European Patent Convention 1973 Art 83
European Patent Convention 1973 Art 84
European Patent Convention 1973 R 29(1)
European Patent Convention 1973 R 29(3)

Keywords:

Support by the description (no), clarity no
Sufficiency of disclosure (no)

Catchwords:

-

Cited decisions:

-

Citing decisions:

T 0435/91
T 0548/91
T 0128/92
T 0143/92
T 0585/92
T 0612/92
T 0634/92
T 0639/92
T 0694/92
T 0923/92
T 0939/92
T 0012/93
T 0169/93
T 0206/93
T 0322/93
T 0329/93
T 0556/93
T 0583/93
T 0659/93
T 1078/93
T 0207/94
T 0656/94
T 0716/94
T 0903/94
T 0919/94
T 0002/95
T 0099/95
T 0311/95
T 0495/95
T 0616/95
T 0691/95
T 0727/95
T 0994/95
T 0289/96
T 0488/96
T 0534/96
T 0842/96
T 0146/97
T 0322/97
T 0354/97
T 0400/97
T 0445/97
T 0586/97
T 0636/97
T 0743/97
T 1055/97
T 1129/97
T 1138/97
T 1213/97
T 0051/98
T 0160/98
T 0217/98
T 0517/98
T 0591/98
T 0687/98
T 0713/98
T 0720/98
T 0924/98
T 0981/98
T 1122/98
T 0364/99
T 0620/99
T 1083/99
T 0190/00
T 0792/00
T 0877/00
T 1076/00
T 1173/00
T 1188/00
T 0118/01
T 0137/01
T 0142/01
T 0219/01
T 0356/01
T 0387/01
T 0524/01
T 0573/01
T 0619/01
T 0632/01
T 0716/01
T 0782/01
T 1082/01
T 1204/01
T 0078/02
T 0378/02
T 0437/02
T 0440/02
T 0609/02
T 1008/02
T 1067/02
T 1124/02
T 0126/03
T 0319/03
T 0487/03
T 1008/03
T 1121/03
T 1155/03
T 1241/03
T 0166/04
T 0337/04
T 0354/04
T 0895/04
T 0094/05
T 0339/05
T 0369/05
T 0673/05
T 1044/05
T 1217/05
T 1466/05
T 0089/06
T 0123/06
T 0142/06
T 0186/06
T 0359/06
T 0381/06
T 0622/06
T 0942/06
T 1063/06
T 1072/06
T 1111/06
T 1140/06
T 1141/06
T 1205/06
T 1362/06
T 1395/06
T 1599/06
T 1604/06
T 1743/06
T 0003/07
T 0061/07
T 0066/07
T 0188/07
T 0234/07
T 0272/07
T 0512/07
T 0519/07
T 0522/07
T 0609/07
T 0617/07
T 0813/07
T 0891/07
T 0386/08
T 0406/08
T 0663/08
T 1468/08
T 1486/08
T 1941/08
T 0115/09
T 0176/09
T 0189/09
T 1966/09
T 2277/09
T 2323/09
T 0347/10
T 0430/10
T 0553/10
T 0812/10
T 1591/10
T 1636/10
T 1693/10
T 1948/10
T 0110/11
T 0307/11
T 0348/11
T 0862/11
T 0958/11
T 1502/11
T 1558/11
T 1626/11
T 1947/11
T 2528/11
T 0123/12
T 0443/12
T 0544/12
T 0608/12
T 0758/12
T 0809/12
T 0889/12
T 1136/12
T 1545/12
T 1694/12
T 1727/12
T 1875/12
T 2090/12
T 2194/12
T 2301/12
T 2344/12
T 0094/13
T 0494/13
T 0498/13
T 1678/13
T 2128/13
T 2229/13
T 2374/13
T 0004/14
T 0088/14
T 0264/14
T 0314/14
T 1111/14
T 1845/14
T 2197/14
T 0078/15
T 0136/15
T 0186/15
T 0387/15
T 0673/15
T 0703/15
T 0861/15
T 1034/15
T 1334/15
T 1439/15
T 1475/15
T 1959/15
T 2225/15
T 0030/16
T 0434/16
T 0875/16
T 1821/16
T 2242/16
T 0298/17
T 1436/17
T 1285/18
T 2015/20

Source: http://www.epo.org/law-practice/case-law-appeals/recent/t910409ex1.html

Date retrieved: 17 May 2021

98 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPO Guidelines - F The European Patent Application

X GL F III 1 Sufficiency of disclosure

X GL F IV 4.10 Result to be achieved

X GL F IV 4.22 Broad claims

X GL F IV 6.1 General remarks

X GL F IV 6.4 Lack of support vs. insufficient disclosure

Offical Journal of the EPO

X OJ EPO SE 1/2021, p179 - Annex 1 - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2020)

X OJ EPO SE 1/2020, p174 - Annex 1 - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2019)

X OJ EPO SE 1/2019, p158 - XVI. - Index of published decisions of the boards of appeal and the Enlarged Board of Appeal - (as at 31 December 2018)

X OJ EPO SE 6/2017, p46 - C. Inventive step

X OJ EPO SE 2/2015, p79 - II. SUFFICIENCY OF DISCLOSURE

X OJ EPO 2015, A102 - Decision of the Enlarged Board of Appeal dated 24 March 2015 - G 3/14

Case Law Book: I Patentability

X CLR I D 1 Introduction

Case Law Book: II Conditions to be met by an Application

X CLR II A 3.2 Indication of all essential features

X CLR II A 5.1 General principles

X CLR II A 5.2 Restrictions on generalising the technical information and examples adduced in the description

X CLR II C 5.3 Examples

X CLR II C 5.4 Invention to be performed over whole range claimed

X CLR II C 7.1.1 General

X CLR II C 8.1 ‍‍Article 83 EPC and support from the description

Case Law Book: III Amendments

X CLR III G 4.3.1 General – "Balance of probabilities"

General Case Law

X T 0435/91 (Detergents) of 9.3.1994

X T 0548/91 (Dipeptides/SCHERING) of 7.2.1994

X T 0128/92 () of 30.11.1994

X T 0585/92 (Deodorant detergent) of 9.2.1995

X T 0612/92 (Monocotyledonous plants/Rijksuniversiteit Leiden) of 28.2.1996

X T 0694/92 (Modifying plant cells) of 8.5.1996

X T 0923/92 (human t-PA) of 8.11.1995

X T 0939/92 (Triazoles) of 12.9.1995

X T 0169/93 (Dandricidal compositions/JOHNSON & JOHNSON) of 10.7.1996

X T 0206/93 () of 30.10.1996

X T 0322/93 () of 2.4.1997

X T 0556/93 () of 19.2.1997

X T 0583/93 () of 4.1.1996

X T 0659/93 () of 7.9.1994

X T 0207/94 (Human beta-interferon) of 8.4.1997

X T 0311/95 (Production of carbon black/WITCO) of 16.6.1999

X T 0616/95 () of 17.2.1999

X T 0727/95 (Cellulose/WEYERSHAEUSER) of 21.5.1999

X T 0994/95 (Oligonucleotide therapeutic agent/MOLECULAR BIOSYSTEMS) of 18.2.1999

X T 0488/96 (Acid chlorides/MITSUI) of 7.12.1999

X T 0445/97 (Detergent blocks/UNILEVER) of 1.4.1998

X T 0586/97 (Aerosol/SOLTEC) of 14.9.2000

X T 0636/97 (Erythropoietin II/KIRIN-AMGEN) of 26.3.1998

X T 0743/97 (Thrombolytic proteins/GENETICS INSTITUTE) of 26.7.2000

X T 1129/97 (benzimidazoles/) of 26.10.2000

X T 1213/97 () of 16.11.2001

X T 0051/98 (Phosphinothrycin/NISSAN) of 24.7.2001

X T 0517/98 () of 17.1.2002

X T 0687/98 () of 11.1.2001

X T 0713/98 () of 17.1.2002

X T 0620/99 (Homologous recombination/CELL GENESIS INC.) of 8.5.2003

X T 0792/00 (Varied binding proteins/DYAX) of 2.7.2002

X T 1076/00 (Impfstoff gegen Drogen/CHILKA Ltd.) of 5.8.2003

X T 1173/00 (Transformer with high-temperature superconductor for locomotives) of 5.6.2003

X T 1188/00 () of 30.4.2003

X T 0387/01 () of 13.1.2004

X T 0524/01 (Recombinant influenza virus/MEDIMMUNE) of 21.10.2005

X T 0716/01 (Bone resorption/WASHINGTON RESEARCH FOUNDATION) of 10.11.2004

X T 0378/02 (Analysis of polynucleotide sequences/OXFORD GENE TECHNOLOGY) of 12.10.2005

X T 0609/02 (AP-1 complex/SALK INSTITUTE) of 27.10.2004

X T 1067/02 (Changed epitopes/NOVOZYMES) of 30.11.2004

X T 1124/02 () of 20.1.2005

X T 1121/03 (Indicator ligands/UNION CARBIDE) of 20.4.2006

X T 1241/03 (Human growth hormone/GENENTECH) of 1.9.2005

X T 0166/04 (Shared memory system / COMPAQ) of 18.7.2007

X T 0094/05 () of 12.7.2007

X T 0339/05 (Meltable ink/OCÃ) of 10.4.2008

X T 0369/05 (Anti-microbial agents/SION) of 27.6.2007

X T 1217/05 () of 8.5.2007

X T 1466/05 (Pyridinoline/SEREX) of 27.7.2007

X T 0123/06 () of 10.1.2008

X T 0142/06 () of 11.3.2008

X T 1063/06 (Reach-through claim/BAYER SCHERING PHARMA AKTIENGESELLSCHAFT) of 3.2.2009

X T 1140/06 () of 13.5.2009

X T 1599/06 (Mycobacterium vaccinating agent/UNIVERSITY OF CALIFORNIA) of 13.9.2007

X T 0061/07 () of 19.8.2008

X T 0512/07 (ACK/NACK-transmission with different power levels/LG) of 22.1.2010

X T 0519/07 (PrÃ©paration du pentachlorobutane/ARKEMA) of 4.9.2008

X T 0617/07 (Monoclonal NGF-antagonist antibodies/LAY LINE) of 4.8.2009

X T 0386/08 (Humanized antibodies to the amyloid beta peptide/WASHINGTON … of 22.11.2010

X T 0189/09 () of 27.7.2011

X T 0347/10 (Dichtmasse/Silu Verwaltung AG) of 7.11.2013

X T 0430/10 (Dotierte FÃ¤llungskieselsÃ¤ure/Evonik) of 28.2.2014

X T 0553/10 (Composite oxide/Nippon Mining) of 11.2.2015

X T 1693/10 () of 9.7.2015

X T 1948/10 (C10-Alkoxylate) of 26.6.2014

X T 0307/11 (Through-pore fraction/IBIDEN) of 19.1.2015

X T 0862/11 (Polyelektrolytkapselsystem /HENKEL) of 17.3.2015

X T 1626/11 () of 21.10.2015

X T 0544/12 () of 22.11.2013

X T 0809/12 (Matchable coated articles/GUARDIAN) of 16.10.2015

X T 1694/12 (Doped cerium oxide / ENERGENICS) of 13.2.2015

X T 1727/12 () of 1.2.2016

X T 2301/12 () of 22.11.2017

X T 2128/13 () of 18.6.2015

X T 0088/14 () of 1.8.2017

X T 1845/14 () of 8.11.2018

X T 0030/16 (Filtration module/SPF) of 8.5.2018